To apply for science and technology innovation board, biopharmaceutical enterprises need to go through layers of inquiries

[pharmaceutical Station industry trends] on July 22, 2019, the science and technology innovation board officially opened According to statistics, in the field of biomedicine, there are 31 biomedical enterprises and 14 companies that have received more than three rounds of inquiries Although kechuangban is good for biomedical enterprises, whether the application conforms to the positioning of kechuangban and whether it has the ability of scientific and technological innovation needs to be tested through multiple rounds of inquiry On the evening of July 22, the Shanghai Stock Exchange disclosed the reply to the implementation letter of feedback on the registration process of microchip biology, and updated the registration draft In the registration process, micro core biology has experienced two rounds of inquiries, pointing out that there are differences at the beginning of the cost capitalization of three R & D projects of the company, and the two rounds of inquiries continue to inquire about the reasons and rationality of the differences According to the disclosure, microchip biology adjusted the cost of relevant projects, and corrected the accounting errors in the financial statements accordingly, so as to smoothly pass the customs in the registration process On July 19, Haier Bio Technology Innovation Board issued a prospectus for public offering of shares (the last draft) In terms of the time of application for listing on science and technology innovation board, Haier biology submitted the application for listing on science and technology innovation board to Shanghai Stock Exchange on April 2, and received the sixth round of examination and inquiry letter from Shanghai Stock Exchange on July 17, which was also the first "examinee" who experienced six rounds of inquiry In the fifth round of inquiry, Haier biology was still asked to give clear opinions on whether it was in line with the national strategy and whether it was in line with the positioning of science and technology innovation board In combination with the requirements of relevant national industrial policies, the company explained in detail that the industry and relevant projects of the enterprise are in line with the national strategic support; the products break the monopoly of foreign technology, play a supporting role in the field of biomedicine, and meet the national strategic requirements On the same day, thermobiology also got the "admission ticket" reviewed by the municipal Party committee The industry of the enterprise is pharmaceutical manufacturing industry The inquiry focuses on the company's equity structure, the basic situation of directors and supervisors; the disclosure content of risk disclosure is too general and vague On July 22, Shenlian biology and Sano medical released the review notice of the municipal Party committee, which will be held on July 31 According to the public information, Shenlian biology is the first synthetic peptide vaccine manufacturer in China The application documents for listing on the science and technology innovation board were accepted on April 2, and now it has gone through five rounds of inquiries Shenlian biology belongs to the pharmaceutical manufacturing industry, which has gone through "five trials" In the third round of inquiry, Shanghai Stock Exchange raised eight questions about Shenlian bio Four questions were asked by Shanghai stock exchange for the sponsor to answer about the source of core technology and cooperative research and development, compliance management, equity change, single product verification opinion, bidding situation, technology innovation board positioning and other questions Sano medical belongs to the industry of special equipment manufacturing, which is mainly engaged in the research, development, production and sales of medical devices The product pipeline covers the key areas of interventional treatment such as cardiovascular, cerebrovascular and structural heart disease In the "four trials", Shanghai stock exchange directly pointed out that since December 2012, the issuer's main competitors have launched a number of other coronary stent products, while the issuer has no reason for the launch of new products, asking the issuer's R & D strength, technology and other information Medesi medesi is a comprehensive pre clinical R & D service cro for biomedicine On July 2, the sponsor supplemented and revised some contents in the reply to the first, second and third rounds of inquiry letters   In view of the issuer's core technology in the field of biopharmaceutics and the reasons for its relatively small share, the reply said: chemical drugs are still the mainstream of drug research and development, and the technical difficulty and complexity of biopharmaceutical research are high, and the requirements for personnel, equipment and capital investment are high The company focuses on pre clinical research At present, the company receives biopharmaceutical research services The proportion of input is relatively low.